

## **Product datasheet for DA3514S**

## VEGF-A (Isoform 165) Human Protein

## **Product data:**

**Product Type:** Recombinant Proteins

**Description:** VEGF-A (Isoform 165) human recombinant protein, 2 μg

Species: Human
Expression Host: Insect
Predicted MW: 45 kDa

**Purity:** >90% by SDS-PAGE and visualised by silver stain

**Buffer:** Presentation State: Purified

State: Lyophilized purified protein

Buffer System: 50 mM Acetic Acid, without stabilizer

**Bioactivity:** Biological: The ED50 for stimulation of cell proliferation by human umbilical vein endothelial

cells for VEGF165 has been determined to be in the range of 1-4 ng/ml.

**Endotoxin:**  $< 0.1 \text{ ng per } \mu \text{g of VEGF}$ 

**Reconstitution Method:** The lyophilized VEGF165 should be restored in 50 mM Acetic Acid to a concentration not

lower than 50 µg/ml. For long term storage we recommend to add at least 0.1% Human or

Bovine Serum Albumin.

**Preparation:** Lyophilized purified protein

**Protein Description:** Recombinant Human Vascular Endothelial Growth Factor165.

**Result by N-terminal sequencing** APMAEGG

Storage: Store lyophilized at 2-8°C for 6 months or at -20°C long term.

After reconstitution store the antibody undiluted at 2-8°C for one month

or (in aliquots) at -20°C long term. Avoid repeated freezing and thawing.

**Stability:** Shelf life: one year from despatch.

**RefSeq:** NP 001020537

 Locus ID:
 7422

 UniProt ID:
 P15692

 Cytogenetics:
 6p21.1

Synonyms: MVCD1; VEGF; VPF



**OriGene Technologies, Inc.** 9620 Medical Center Drive, Ste 200

CN: techsupport@origene.cn

Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com



**Summary:** 

This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative inframe translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. The levels of VEGF are increased during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus promoting inflammation by facilitating recruitment of inflammatory cells, and by increasing the level of angiopoietin II (Ang II), one of two products of the SARS-CoV-2 binding target, angiotensin-converting enzyme 2 (ACE2). In turn, Ang II facilitates the elevation of VEGF, thus forming a vicious cycle in the release of inflammatory cytokines. [provided by RefSeq, Jun 2020]

**Protein Families:** 

Druggable Genome, Secreted Protein

**Protein Pathways:** 

Bladder cancer, Cytokine-cytokine receptor interaction, Focal adhesion, mTOR signaling pathway, Pancreatic cancer, Pathways in cancer, Renal cell carcinoma, VEGF signaling pathway

## **Product images:**

